Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Regeneron Pharmaceuticals' Otarmeni wins FDA approval for otoferlin-deficient congenital hearing loss following Ph1/2 success
Gene therapy, hearing loss, monoclonal antibody, otoferlin, OTOF gene, congenital deafness - Read more

Atrium Therapeutics earns $15M milestone from Bristol Myers Squibb under cardiovascular RNA therapy collaboration
Licensing deal, cardiovascular, RNA therapeutics, milestone payments, royalties - Read more

Dogwood Therapeutics, PRIDCor Therapeutics partner on antiviral assets IMC-1 and IMC-2, up to $100M potential payments
Co-development, infectious disease, small molecule, royalties, milestone payments - Read more

Struggling with your sales & marketing stack as you’re selling into biotech & life sciences? We’re here to help with a free webinar.

Come learn the importance of brand establishment, proper segmentation of your target ICP, thought leadership content development, omnichannel approaches to outreach campaigns, and personalized, high-touch outreach.

Presented by Hapatune, a boutique marketing firm for bioprocess and life science companies, and Science 2 Sales, a lead-gen and GTM agency helping companies sell into biotech, life sciences, and pharma.

Grab your spot before it’s all filled out!

Novo Nordisk's Rybelsus (semaglutide) meets Ph3 goals in pediatric type 2 diabetes, supporting label expansion filings
Small molecule, metabolic, GLP-1 receptor agonist, type 2 diabetes, pediatric population - Read more

Mozart Therapeutics' MTX-101 (CD8 Treg modulator) shows positive Ph1b interim data in adults with Stage 3 type 1 diabetes
Small molecule, autoimmune, type 1 diabetes, CD8 Treg modulator, immunomodulation, beta cell preservation - Read more

Sanofi beats Q1 sales expectations with Dupixent up 31%, reaffirms 2026 growth guidance
Monoclonal antibody, autoimmune, financial, competitive, leadership change - Read more

Roche bets on giredestrant and obesity drugs to offset $6.7B biosimilar sales threat through 2030
Small molecule, oncology, obesity, competitive, strategic - Read more

Kurma Partners closes €215M ($251M) Biofund IV to back around 20 European biotechs
Venture capital, biotech investing, antibody-drug conjugate, obesity - Read more

Celerion receives undisclosed THL Partners investment to expand clinical pharmacology capabilities
CRO, clinical pharmacology, bioanalytical services, Phase 1 studies - Read more

Ferrosa Therapeutics raises $3.5M Seed funding to advance bispecific antibody for anemia of inflammation
Antibody, anemia, autoimmune, preclinical, bispecific - Read more

Gravity Rail raises $2.75M seed funding, AI platform for patient communications
AI/ML platform, patient communication, software platform, services - Read more [Paywall]

Evonik invests €80M ($93.6M) in Slovakia facility to boost fermentation capabilities, adding 50 jobs
Fermentation/biotech manufacturing, pharmaceutical ingredients, strategic, major transaction - Read more

Deerfield launches Prismatiq software to help pharma brand teams manage sales rep content and compliance
Pharma sales software, operational, competitive, strategic - Read more

Regeneron joins White House 'most favored nation' drug pricing deal, pledging Medicaid price reductions aligned with developed nations
Small molecule, cardiovascular, strategic, regulatory, financial - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

FDA rejects Grace Therapeutics' GTx-104 (nimodipine) for aneurysmal subarachnoid haemorrhage over CMC concerns after Ph3
Small molecule, neurological, nanoparticle formulation, aneurysmal subarachnoid haemorrhage, nimodipine, cerebral vasospasm - Read more

Roche Q1 sales drop 5% to CHF 14.7B ($18.73B), hurt by strong Swiss franc despite 6% constant-currency growth
Small molecule, oncology, financial, revenue impact - Read more

Unnamed pharma files citizen petition urging FDA to halt public release of drug rejection letters
FDA transparency, regulatory, operational, competitive - Read more

Pfizer discontinues Ph1 trial of (PF-08046037), PD-L1-targeting immunostimulatory drug conjugate, across multiple cancers
Antibody, cancer, immunostimulatory drug conjugate, PD-L1, non-small cell lung cancer, TLR7 agonist - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here